Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Summary

To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17 years.

Timeline

Start

2018-10-24

Primary completion

2018-11-23

Completion

2018-11-23

Drugs

Indications